Printer Friendly
The Free Library
14,757,244 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Advanced Cell Technology to Host Conference Call and Webcast to Discuss Recent Developments and Planned Acquisition of Mytogen.


Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , William M. Caldwell, IV and Chief Development Officer, Dr. Pedro Huertas, to Discuss Planned Transition to Clinical Development Company and Other Topics, on Thursday, June 7, at 1:00PM ET

ALAMEDA, Calif -- Advanced Cell Technology, Inc. (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
: ACTC ACTC Apple Certified Technical Coordinator
ACTC Almaden Cycle Touring Club
ACTC Associated Colleges of the Twin Cities
ACTC All Ceylon Tamil Congress (Sri Lanka)
ACTC Association Canadienne de Télévision par Câble
) will host a conference call, which will be simultaneously webcast, on Thursday, June 7th, at 1:00PM ET. The purpose of the call is to discuss recent company developments. Among the topics to be discussed is the Company's entry into a Letter of Intent to purchase Mytogen, Inc. and its Myoblast myoblast /myo·blast/ (mi´o-blast) an embryonic cell which becomes a muscle cell or fiber.myoblas´tic

my·o·blast
n.
A primitive muscle cell having the potential to develop into a muscle fiber.
 Program for the treatment of heart failure, and its plans to commence Phase II human clinical trials to treat heart failure using Mytogen's Autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism.

au·tol·o·gous
adj.
1.
 Myoblast Stem Cell Therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs .

The call will be hosted by William M. Caldwell, IV, Chairman and Chief Executive Officer, and Pedro Huertas, M.D., Ph.D., Chief Development Officer.

William M. Caldwell, IV commented, "This planned acquisition, if completed, will hasten Advanced Cell's transformation from a preclinical development company to a clinical therapeutic company. Our Chief Development Officer, Dr. Pedro Huertas, and I are excited to have the opportunity to discuss this and other company developments with our investors and other interested parties, on Thursday's call."

Details of the call are below. Participants should dial in at least ten minutes prior to the call.
Thursday, June 7, 1:00PM ET
---------------------------

Live participant dial-in:
Toll-free:      866-585-6398
International:  416-849-9626

Replay:
Toll-free:      866-245-6755
International:  416-849-2696
Passcode (for replay only): 517429
Teleconference Replay Available Until: 6/14/07, 11:59 PM


A webcast of the call will be available through Advanced Cell's website, at www.advancedcell.com. The webcast will be available for replay through July 7, 2007.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying stem cell stem cell

In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult.
 technology in the emerging field of regenerative re·gen·er·a·tive  
adj.
1. Of, relating to, or marked by regeneration.

2. Tending to regenerate.



re·gen
 medicine. The company operates facilities in Alameda, California Alameda is a city in Alameda County, California, United States. It is located on a small island of the same name next to Oakland, California in the San Francisco Bay. An additional part of the city is Bay Farm Island, which is adjacent to the Oakland International Airport.  and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com

Forward-Looking Statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 4, 2007
Words:591
Previous Article:F-Secure's Award-Winning Consumer Products Updated to Support Windows Vista.
Next Article:31st Internationalization & Unicode Conference to Feature New Content on New Technologies, Academic Topics, Web Mail and Hot Topics in...
Topics:



Related Articles
CORRECTING and REPLACING SFBC International Provides 2003 Guidance to Reflect Recent Stock Offering and 2004 Guidance.
Cytokinetics to Announce First Quarter Results on June 16, 2004.
Cytokinetics to Announce Second Quarter Results on July 28, 2004.
Advanced Cell Technology's Chief Scientific Officer Michael West, Ph.D. to be Featured Guest Speaker at Rodman & Renshaw Techvest 7th Annual...
GenVec Completes Previously Announced Sale of Myoblast Cell Therapy Program.
WebAlert: Advanced Cell to Hold Conference Call Today at 12 Noon ET to Discuss Technique to Produce Stem Cells without Harming Embryo; Company to...
Advanced Cell Technology Announces Investor Conference Call to Be Held Friday January 19 to Discuss Key Events and Progress in Stem Cell-Based...
WebAlert: Advanced Cell Technology Conference Call to Start Today at 12 Noon ET.
Illumina Announces the Completion of Its Acquisition of Solexa.
Advanced Cell Technology Enters Into Letter of Intent to Acquire Mytogen, Inc. and Proceed with the Human Clinical Trials Utilizing Myoblasts for the...

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles